BioSpace News Archive

Nearsightedness has risen dramatically over the last 50 years. If nothing is done to help slow the increase, half the world’s population may be nearsighted by the year 2050.

Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, announced an expansion of the clinical development program for the Company’s lead asset, ATH434, in patients with Multiple System Atrophy, a rare and rapidly progressing Parkinsonian disorder.

Telix Pharmaceuticals Limited is pleased to announce the first set of peer-reviewed results from the IPAX-1 Ph I/II study of TLX101 in combination with external beam radiation therapy in recurrent glioblastoma multiforme has been delivered as a late breaking oral presentation at the Congress of Neurological Surgeons Annual Meeting currently taking place in Austin, Texas.

Context Therapeutics Inc. announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $25.0 million, before deducting underwriting discounts, commissions and offering expenses.

In a release issued under the same headline on Tuesday, October 12th from Neuronetics, Inc., please note that the Safe Harbor Statement was inadvertently omitted.

Thermo Fisher Scientific Inc. announced that it has priced an offering of $5.85 billion aggregate principal amount of the following notes, each issued at par:.

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021 after the markets close. At 5:00 p.m. EDT / 2:00 p.m.

Cano Health, Inc. (NYSE: CANO or the “Company”), a leading value-based primary care provider for seniors and underserved communities, will host a conference call on Tuesday, November 9, 2021, at 8:30 AM Eastern Time to review the Company’s business and financial results for the third quarter ended September 30, 2021.

Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), in collaboration with Professor Toni Cathomen, scientific director at the Center for Chronic Immunodeficiency Medical Center at the University of Freiburg, Germany, will present two oral presentations at the European Society of Gene and Cell Therapy (ESGCT) Congress to be held virtually from October 19-22, 2021.

Aadi Bioscience, Inc. announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at H.C. Wainwright’s 2nd Annual Precision Oncology Conference, which will be held virtually.